Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | P4HB | P07237 | 4/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
| ▸ | CA4 | P22748 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.60 |
| ▸ | MPI | P34949 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510457 | 0.88 | NQO2 (0.72) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL180904 | 0.85 | KDM4E (0.69) | P4HBACHECA12CA2AKR1B1 | |
| SCHEMBL1278982 | 0.84 | CYP3A4 (0.69) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL1287866 | 0.84 | CYP3A4 (0.69) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL9992609 | 0.84 | CYP3A4 (0.69) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL18670353 | 0.84 | CYP3A4 (0.69) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL7601750 | 0.81 | KDM4E (0.73) | P4HBACHECA12CA2AKR1B1 | |
| SCHEMBL6903921 | 0.81 | NQO2 (0.70) | NQO2P4HBACHECA12CA2 | |
| SCHEMBL17938818 | 0.81 | KDM4E (0.73) | P4HBACHECA12CA2AKR1B1 | |
| SCHEMBL2510346 | 0.81 | KDM4E (0.73) | P4HBACHECA12CA2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960430-B2 | Flavonoid complexes with cyclodextrins | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1718658-B1 | FLAVONOID COMPLEXES COMPRISING CYCLODEXTRINS | MERCK PATENT GMBH (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20080199414-A1 | COSMETIC FORMULATION COMPRISING FLAVONOID DERIVATIVES | WIRTH CORINNA | 2008-08-21 | — | — | US | disclosed |
| EP-1847182-A2 | Foodstuffs or dietary supplements containing flavonoid derivates | MERCK PATENT GmbH (DE) | 2007-10-24 | — | — | EP | disclosed |
| US-20070155695-A1 | Flavonoid complexes with cyclodextrins | EUROPEAN BRAND PARTICIPATIONS SA (LU) | 2007-07-05 | — | — | US | disclosed |
| EP-1718658-A1 | FLAVONOID COMPLEXES COMPRISING CYCLODEXTRINS | MERCK PATENT GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1393733-B1 | Use of flavonoid-derivatives for the treatment of atopic eczema | MERCK PATENT GMBH (DE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005068484-A1 | FLAVONOID COMPLEXES COMPRISING CYCLODEXTRINS | MERCK PATENT GMBH (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-20040081675-A1 | Cosmetic formulations containing flavonoid derivatives | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040053860-A1 | Flavonoid derivatives for the treatment of eczema | MERCK PATENT GMBH (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1393733-A1 | Flavonoid-derivate for the treatment of eczema | MERCK PATENT GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1363594-A1 | COSMETIC FORMULATIONS CONTAINING FLAVONOID DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002069926-A1 | COSMETIC FORMULATIONS CONTAINING FLAVONOID DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155695-A1 | Flavonoid complexes with cyclodextrins | TYR, DPM1, CYP2F1 | NQO2 1189/4885P4HB 903/4885ACHE 2924/4885 |
| US-20040081675-A1 | Cosmetic formulations containing flavonoid derivatives | TYR, MITF, TEAD3 | NQO2 219/4885P4HB 3576/4885ACHE 1172/4885 |
| US-20040053860-A1 | Flavonoid derivatives for the treatment of eczema | TSLP, CYP51A1, TYR | NQO2 96/4885P4HB 2498/4885ACHE 838/4885 |
| US-20080199414-A1 | COSMETIC FORMULATION COMPRISING FLAVONOID DERIVATIVES | TYR, MITF, TEAD3 | NQO2 251/4885P4HB 3165/4885ACHE 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.